The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy
Open accessAbstract
Diabetic neuropathy, with its major clinical sequels, notably neuropathic pain, foot ulcers, and autonomic dysfunction, is associated with substantial morbidity, increased risk of mortality, and reduced quality of life.Despite its major clinical impact, diabetic neuropathy remains underdiagnosed and undertreated.Moreover, the evidence supporting a benefit for causal treatment is weak at least in patients with type 2 diabetes, and current pharmacotherapy is largely limited to symptomatic treatment options.Thus, a better understanding of the underlying pathophysiology is mandatory for translation into new diagnostic and treatment approaches.Improved knowledge about pathogenic pathways implicated in the development of diabetic neuropathy could lead to novel diagnostic techniques that have the potential of improving the early detection of neuropathy in diabetes and prediabetes to eventually embark on new treatment strategies.In this review, we first provide an overview on the current clinical aspects and illustrate the pathogenetic concepts of (pre)diabetic neuropathy.We then describe the biomarkers emerging from these concepts and novel diagnostic tools and appraise their utility in the early detection and prediction of predominantly distal sensorimotor polyneuropathy.Finally, we discuss the evidence for and limitations of the current and novel therapy options with particular emphasis on lifestyle modification and pathogenesis-derived treatment approaches.Altogether, recent years have brought forth a multitude of emerging biomarkers reflecting different pathogenic pathways such as oxidative stress and inflammation and diagnostic tools for an early detection and prediction of (pre)diabetic neuropathy.Ultimately, these insights should culminate in improving our therapeutic armamentarium against this common and debilitating or even life-threatening condition.(Endocrine Reviews 40: 153 -192, 2019) T he st century saw the further increase in the prevalence of diabetes and prediabetes (-).Diabetes leads to a serious increase in morbidity and mortality due to cardiovascular disease (CVD) (-) but also due to its microvascular complications (, ).Of note, diabetic foot complications are frequent in diabetes, difficult to heal, with a tendency to recur, sometimes presenting as emergencies, and generally they carry a sinister prognosis (-).In this context, prediabetes is receiving more attention, because it is now appreciated as a stage of already incipient vascular damage rather than just a condition of borderline increased glucose values ().Both macrovascular and microvascular disease may have their beginning in prediabetes and may adversely affect morbidity already at this stage ().
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Diabetic foot ulcers and their recurrence
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1615439 · Cited by 4,376
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Self-citationCardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A classification of chronic pain for ICD-11
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., et al. (2015) · Pain · doi:10.1097/j.pain.0000000000000160 · Cited by 2,822
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Self-citationNeuropathic Pain: A Maladaptive Response of the Nervous System to Damage
Costigan, M., Scholz, J., & Woolf, C. J. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135531 · Cited by 2,025
Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase
Li, Y., Huang, T.-T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., Noble, L. J., Yoshimura, M. P., Berger, C., Chan, P. H., et al. (1995) · Nature Genetics · doi:10.1038/ng1295-376 · Cited by 1,789
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop‐Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1239 · Cited by 957
Self-citationBoussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Neuropathic pain: mechanisms and their clinical implications
Cohen, S. P., & Mao, J. (2014) · BMJ · doi:10.1136/bmj.f7656 · Cited by 802
Hammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine · doi:10.1038/nm834 · Cited by 785
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
4. Lifestyle Management: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s004 · Cited by 563
Gong, Q., Gregg, E. W., Wang, J., An, Y., Zhang, P., Yang, W., Li, H., Li, H., Jiang, Y., Shuai, Y., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1948-9 · Cited by 251
Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., & Mielck, A. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00555.x · Cited by 249
Self-citationAndersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2062 · Cited by 248
Tavakoli, M., Ferdousi, M., Petropoulos, I. N., Morris, J., Pritchard, N., Zhivov, A., Ziegler, D., Pacaud, D., Romanchuk, K., Perkins, B. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2311 · Cited by 222
Self-citationCameron, N. E., Tuck, Z., McCabe, L., & Cotter, M. A. (2001) · Diabetologia · doi:10.1007/s001250100626 · Cited by 97
Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance
Putz, Z., Tabák, A. G., Tóth, N., Istenes, I., Németh, N., Gandhi, R. A., Hermányi, Z., Keresztes, K., Jermendy, G., Tesfaye, S., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1406 · Cited by 90
Stojadinovic, O., Yin, N., Lehmann, J., Pastar, I., Kirsner, R. S., & Tomic-Canic, M. (2013) · Immunologic Research · doi:10.1007/s12026-013-8474-z · Cited by 88
Cited by
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30187-1 · Cited by 600
Self-citationPathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease
Horton, W. B., & Barrett, E. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa025 · Cited by 424
Metadata
- Authors
- Bönhof, G. J., Herder, C., Strom, A., Papanas, N., Roden, M., & Ziegler, D.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-09-25
- Volume
- 40
- Issue
- 1
- Pages
- 153-192
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2893710862
- Cited by
- 221
- References
- 28
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.